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Abstract Bacillus thuringiensis Cry1Ac N-endotoxin specifi-
cally binds a 115-kDa aminopeptidase-N purified from Manduca
sexta midgut. Cry1Ac domain III mutations were constructed
around a putative sugar-binding pocket and binding to purified
aminopeptidase-N and brush border membrane vesicles (BBMV)
was compared to toxicity. Q509A, R511A, Y513A, and 509^511
(QNR-AAA) eliminated aminopeptidase-N binding and reduced
binding to BBMV. However, toxicity decreased no more than
two-fold, indicating activity is not directly correlated with
aminopeptidase-N binding. Analysis of toxin binding to amino-
peptidase-N in M. sexta is therefore insufficient for predicting
toxicity. Mutants retained binding, however, to another BBMV
site, suggesting alternative receptors may compensate in vivo.
z 1999 Federation of European Biochemical Societies.
Key words: Aminopeptidase-N; Brush border membrane
vesicle; Surface plasmon resonance; N-Acetylgalactosamine;
Bacillus thuringiensis
1. Introduction
Bacillus thuringiensis (Bt) produces insecticidal crystal pro-
teins during its sporulation process. The crystal inclusions are
solubilized in the insect midgut to produce protoxin which is
further digested to an active toxin fragment by midgut pro-
teases. The activated toxin binds to speci¢c receptors on the
surface of the midgut epithelial cell membrane. Membrane-
bound toxin is believed to be inserted into the lipid membrane
and form pores or ion channels, leading to insect death. The
receptor-binding step is considered to be critical to its mode of
action and in resistance development.
Receptor-binding properties have been examined with
brush border membrane vesicles (BBMV) prepared from the
insect larval midguts and labeled Bt toxins [1]. Recently, sur-
face plasmon resonance (SPR) techniques have been employed
as well to study interactions between toxins and puri¢ed re-
ceptors [2^6]. Aminopeptidase-N (APN) was ¢rst identi¢ed [7]
and puri¢ed [8] as a Cry1Ac receptor from Manduca sexta
BBMV. APN from other insects were also identi¢ed as
Cry1Ac receptors [9^11]. Cry1Ac binding to APN is inhibited
speci¢cally by N-acetylgalactosamine (GalNAc) [2,3,12], pro-
viding evidence that a carbohydrate moiety on APN is in-
volved in toxin binding. A 210-kDa cadherin-like Cry1A-
binding protein from M. sexta has also been reported [13,14].
The X-ray crystal structure of Cry1Aa reveals a three-do-
main composition [15]. Domain I, composed of seven K-heli-
ces, is important for membrane insertion and pore formation.
Domain II, composed of antiparallel L-sheets, is involved in
binding to BBMV and to puri¢ed receptors. Domain III,
composed of a L-sheet sandwich, is also involved in receptor
binding and ion-channel conductivity. Domain III shares the
typical jelly roll topology found in other sugar-binding pro-
teins that often lack primary sequence homology. Similar
folds can be seen in sugar-binding bacterial toxins, viral pro-
teins, glycosidases, and plant, animal, and fungal lectins. Lec-
tins, however, have more than one sugar-binding site, and
thus, can agglutinate cells [16]. Due to its abundance in in-
testinal tracts [17], many pathogenic lectins appear to have
evolved to target GalNAc.
Previously, we have constructed alanine substitution muta-
tions (residues 502^523) in the L-sheet in domain III of
Cry1Ac toxin, and their biological activities and BBMV bind-
ing to several insects, including M. sexta, Lymantria dispar,
Heliothis virescens were examined [18,19]. Mutations at the
residues Q509, R511, and Y513 a¡ected toxicity and BBMV
binding to these insects. In the present paper, we have further
examined the binding properties of these mutant toxins to M.
sexta APN using SPR to evaluate the relationship between
toxicity and puri¢ed receptor binding.
2. Materials and methods
2.1. Mutant toxin construction, expression, and puri¢cation
A putative 3D model of Cry1Ac was constructed by homology
modeling from Cry1Aa [15] using SWISS-MODEL [20] and visualized
using SWISS-PdbViewer v.3.1 with Q3D rendering. Site-directed mu-
tagenesis of cry1Ac1 [21] was carried out by the Kunkel method [22]
and transformed into Escherichia coli MV1190 for expression. Active
65-kDa Cry1Ac toxins were produced as described previously [23].
Active proteins were further puri¢ed by size-exclusion chromatogra-
phy on a Superdex 200 column (Amersham Pharmacia Biotech).
Monomeric fractions were collected, and MW veri¢ed by dynamic
light scattering (DynaPro-801). The monomeric form of the toxin
was not found to multimerize in storage once column-puri¢ed from
aggregate toxin forms. Mutants were analyzed by 10% SDS-PAGE
and shown to be equal in size with wild type after trypsinization and
size-exclusion puri¢cation.
2.2. BBMV preparation and binding studies
M. sexta BBMV were prepared by the magnesium precipitation
method [24]. Iodination of toxins, BBMV competition binding, and
ligand blotting were conducted as described previously [23,25].
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2.3. SPR analysis of binding to puri¢ed M. sexta APN
M. sexta APN was puri¢ed and tested for Cry1Ac binding ability as
described in [6]. SPR technique was carried out using a BIAcore 2000
(Biacore AB, Uppsala, Sweden) with a CM5 sensor chip. All toxins
were dialyzed into HBS (10 mM HEPES, 150 mM NaCl, 3.4 mM
EDTA pH 7.4). Amine coupling of the soluble, 115-kDa Cry1Ac-
binding APN was achieved in ammonium acetate, pH 4.2. Five
randomized toxin concentrations (10^1000 nM) were ‘kinjected’ (low
dispersion injection for kinetic measurements) at 30 Wl/min. The ex-
periment was repeated on three di¡erent APN-containing £ow cells
with two independent APN preparations. APN was regenerated by
two 15^30-Wl pulses of 10 mM NaOH, pH 11.0. Wild-type Cry1Ac
binding was checked before and after all mutants to ensure the integ-
rity of APN. Fittings were done globally using BIAevaluation 3.0. All
models available with the software were tested, and the heterogeneity
model (T+R1DTR1, T+R2DTR2) was chosen as the best ¢t
(M26 1). Initial global values for kon and koff were obtained from
local ¢ttings. Standard error is 6 10% of the reported value for all
apparent rate constants.
3. Results
3.1. Cry1Ac domain III mutants and biological activities to M.
sexta
Alanine substitutions were made in cry1Ac1 at Q509, N510,
R511, Y513, and at residues 509QNR511. When expressed, all
mutants formed toxins that were stable after trypsin activa-
tion and analyzed by 10% SDS-PAGE (not shown). CD spec-
tra of the mutant toxins were comparable to that of wild-type
Cry1Ac, suggesting that the mutations do not alter structural
integrity [19]. In sequence alignments with cry1Aa and
cry1Ab, these residues are found in a non-conserved loop
region extending from L-15 and continuing into L-16. A 3D
structure of Cry1Ac was homology-modeled from Cry1Aa.
Where a relatively £at surface is displayed on Cry1Aa, a cav-
ity is predicted to form on the surface of Cry1Ac domain III.
The mutants presented in this study line the bottom of the
cavity (Fig. 1). Bioassays revealed that the mutant toxins are
about two-fold less toxic than the wild-type Cry1Ac toxin
(LC50 = 4.7 ng/cm2). The range of LC50 values for the mutant
toxins is 7.5^9.8 ng/cm2. Detailed bioassay data are presented
elsewhere [19].
3.2. Real-time binding to puri¢ed APN
A BIAcore 2000 enabled the use of the SPR technique to
monitor changes in mass on a surface of immobilized receptor
as toxin is injected. Apparent rate constants were obtained by
global analysis using BIAevaluation 3.0. Monomeric Cry1Ac
bound M. sexta APN heterogeneously (Fig. 2) (T+R1DTR1,
T+R2DTR2), con¢rming previously published results [2].
Wild-type apparent rate constants obtained were kon1 = 3e5
M31 s31, koff1 = 3e32 s31 and kon2 = 4.4e4 M31 s31,
koff2 = 3.4e33 s31, yielding KD a⁄nities of 141 nM and 77
nM, respectively. N510A bound APN with wild-type a⁄nity
(apparent rate constants were within standard error range of
wild-type). No binding to APN was seen for Q509, R511,
Y513, or QNR-AAA at any concentration. Therefore, no
rate constants were measured for these mutant toxins.
3.3. BBMV receptor-toxin overlay
M. sexta BBMV proteins were separated by 6% SDS-
Fig. 1. Molecular model of Cry1Ac domain III GalNAc-binding
pocket. Residues lining the cavity mouth are in black. GalNAc
structure is shown for size comparison.
Fig. 2. Sensorgram overlay comparing wild-type Cry1Ac and mu-
tant toxin binding (100 nM) to puri¢ed M. sexta APN.
Fig. 3. Binding of 125I-labeled Cry1Ac (lane 1), N510A (lane 2), and
QNR-AAA toxin (lane 3) to M. sexta BBMV proteins. BBMV pro-
teins (20 Wg) were separated by 6% SDS-PAGE, transferred to
PVDF, and probed with labeled toxins.
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PAGE, transferred to PVDF membrane, and probed with
125I-labeled toxins. Cry1Ac bound to a band slightly above
200 kDa, as well as a 120-kDa band, the molecular size of
APN (Fig. 3). These results are in agreement with earlier
¢ndings for Cry1Ac [26]. N510A showed similar binding to
wild-type. Conversely, labeled QNR-AAA showed no visible
binding within the APN size range, but did retain binding to
the higher band.
3.4. Binding to BBMV
In previous BBMV competition assays, we have shown that
QNR-AAA and individual mutant toxins Q509A, R511A,
and Y513A did not compete as well with labeled Cry1Ac
for binding to BBMV compared to wild-type self-competition
[19]. The a⁄nity of Cry1Ac and QNR-AAA for M. sexta
BBMV receptor sites was 3.9 ( þ 1.2) and 38.2 ( þ 5.3) nM
respectively, re£ecting a 10-fold di¡erence. To further inves-
tigate the nature of QNR-AAA’s reduced a⁄nity, a reciprocal
competition binding assay was conducted. Labeled QNR-
AAA was competed with cold QNR-AAA or cold wild-type
(Fig. 4). Cold Cry1Ac competes with labeled QNR-AAA with
the same a⁄nity that cold QNR-AAA does. The combined
results of the reciprocal binding studies do not support the
hypothesis that the QNR-AAA mutant toxin has reduced af-
¢nity for only APN. Rather, they suggest that Cry1Ac binds
to multiple receptor sites, and that the QNR-AAA mutant
toxin loses binding to APN sites while retaining binding to
others.
4. Discussion
In the present study, a functional role for domain III of
Cry1Ac was investigated by a series of mutations in a L-sheet
region particular to Cry1Ac. Our results show considerable
di¡erences between binding a⁄nities of wild-type and mutant
toxin to M. sexta APN compared to di¡erences in toxicity.
The requirement of domain III residues for binding to
M. sexta APN correlates with the ¢ndings in studies using
domain-switched mutants [6,27,28] and ligand overlay blots
using M. sexta BBMV [29]. Additionally, the loss of binding
by domain III mutants to Lymantria dispar and Heliothis
virescens BBMV [19] suggests these amino acids have a com-
mon role in binding to insect APNs. This idea is supported by
studies that showed GalNAc inhibits Cry1Ac binding to both
L. dispar and H. virescens APNs using the SPR technique [3,4]
A molecular model of Cry1Ac predicted these mutations to
be located around a unique cavity that is not present on
Cry1Aa. Residues W545 and G546 complete the upper por-
tion of the cavity mouth (Fig. 1). N510 appears inside, and
not surrounding, the cavity. The lip surrounding this inden-
tation presents residues in Cry1Ac entirely non-conserved
with Cry1Aa. Furthermore, the Cry1Aa amino acids ‘¢lling
in’ the cavity from L-sheet 22 (S581, V582, F583) are missing
in Cry1Ac, allowing G584 and N585 to line the pocket un-
obtrusively. GalNAc is known to inhibit Cry1Ac binding to
puri¢ed APN, but not Cry1Aa [2]. This model provides evi-
dence of structural di¡erences between Cry1Ac and other
Cry1A toxins that may account for the sugar-binding specif-
icity of Cry1Ac.
Our experiments provide evidence that demonstrates
Cry1Ac has multiple receptor speci¢city, which is lost when
domain III mutations are constructed around the putative
cavity. SPR studies and BBMV ligand blots showed QNR-
AAA lost binding to APN from M. sexta BBMV, suggesting
the unique cavity in Cry1Ac domain III is necessary for APN
binding. However, QNR-AAA retained binding to another
Cry1Ac-binding band that is also bound by wild-type. The
presence of at least one other Cry1Ac-binding component in
BBMV indicates that APN does not act as a lone receptor.
Additionally, despite QNR-AAA’s 10-fold loss of a⁄nity for
M. sexta BBMV in competition assays, it remains an equal
competitor as wild-type for its binding to other receptor sites
(Fig. 4). Therefore, the Cry1Ac mechanism of binding to APN
(by domain III-sugar contact) may be non-essential for bind-
ing to other sites. Evidence of GalNAc-independent binding
mechanisms has been observed in BBMV prepared from the
anterior subregion of M. sexta midgut [30]. Furthermore, a
report using various ligand binding protocols [26] found that
a 210-kDa cadherin-like glycoprotein, BT-R1, from M. sexta
binds Cry1A proteins. These data were strongly supported by
the fact that cloned BT-R1 expressed in insect cells still bound
Cry1A toxins [31]. A similar cadherin-like glycoprotein,
BtR175, has been cloned from Bombyx mori that binds
Cry1Aa [32] in a GalNAc-independent manner. Antibodies
to BtR175 block insecticidal action in vivo [33].
Given the binding and toxicity contradiction found in this
study, one possible explanation of our data is that while re-
ceptor recognition did not occur in in vitro binding studies,
over the time course of a bioassay (5 days), only minor re-
ductions in insecticidal activity occur. Alternatively, the ¢rst
instar larvae used in bioassays and ¢fth instar larvae used for
BBMV preparations may di¡er in a way that causes loss of
binding at a later stage but not an earlier one. However,
mutations in the domain II of several Cry toxins have been
shown to reduce both toxicity and binding to BBMV in nu-
merous publications. A second model to explain the contra-
diction is that Cry1Ac binding to another receptor is more
functionally critical than binding to APN receptor. However,
if APN acts as a binding protein without allowing the pore-
Fig. 4. Binding of Cry1Ac and domain III mutant toxins to M. sex-
ta BBMV. 125I-QNR-AAA (2 nM) was incubated with 10 Wg
BBMV in the presence of increasing concentrations of unlabeled
Cry1Ac (b) or unlabeled QNR-AAA (a).
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formation step, it should be considered a sequestering protein.
In this model, mutants that lose binding to APN should be
free to bind functional sites, thus augmenting toxicity. This is
not the result of our bioassays. About two-fold less activity
was observed for these mutant toxins. For APN to be non-
critical in the gut environment it would have to be present in
signi¢cantly lower ratios than other receptors, making loss of
binding irrelevant. Neither BBMV ligand blots (Fig. 3) nor
gut enzyme studies suggest a paucity of APN in insect guts.
Furthermore, APNs from M. sexta and H. virescens have
been reconstituted into membranes and caused toxin-induced
pores to form [34]. In a ¢nal possible scenario, APN serves as
a functional receptor among others. Although the binding to
APN was completely abolished, binding to other receptors
could be increased, which, in turn, maintain the toxicity
over the time course of a bioassay. In this model, a mutant
with enhanced a⁄nity for APN might still enhance toxicity.
We note a recent report published while this paper was in
preparation. The authors found similar Cry1Ac domain III
mutations had no e¡ect on toxicity to M. sexta [29]. The
mutant toxins had reduced a⁄nity for M. sexta BBMV as
well as ability to induce BBMV permeability. Also, the mu-
tants lost binding to the APN component of BBMV, as does
Cry1Ac when competed with GalNAc. Here, we further ad-
vance a model for Cry1Ac receptor binding in this study by
demonstrating a total loss of mutant toxin binding to puri¢ed
APN using real-time kinetics. We see binding to other recep-
tor sites by ligand blotting and reciprocal competition binding
assays, which might account for the small changes in toxicity.
Finally, we show a structural di¡erence between Cry1Ac and
Cry1Aa, which explains why Cry1Ac has sugar-binding spe-
ci¢city.
Mutations where loss of binding to puri¢ed APN is well
correlated with loss of toxicity have been observed in Cry1Ac
and Cry1Ab when domain II loop residues were altered (J.
Jenkins and D. Dean, unpublished). A comprehensive binding
model of domain III and domain II is under investigation to
better understand the relationship between receptor binding
and insecticidal activity.
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